11174 RESULTS
COMMENT The real nail in the coffin for any drug whatsoever for the blind empirical treatment of Alzheimer's disease is knowing what causes the disease, which is (quite simply) vacuum steam-deodorized, Vitamin E-depleted polyunsaturated vegetable oils (soya
COMMENT This is an elegant paper demonstrating downstream events that tie Abeta toxicity and oxidative stress. 0 lhtsai
COMMENT This paper by Mark Cookson’s group is very exciting: While it starts answering some of the numerous issues regarding PINK1 function, at the same time it poses new, intriguing questions. There are at least two important messages in this paper. First, the a
COMMENT The Alzheimer's Disease Cooperative Study Group MCI trial results regarding donepezil are very encouraging and should be used to stimulate a primary prevention trial. The New England Journal report did not offer a molecular mechanism to explain donep
COMMENT comment regarding the Petersen et al. MCI trial results is that better drugs than those currently
COMMENT RNAi Therapy Works in Animal Models Scott Harper et al. recently demonstrated that RNA interference (RNAi) can treat Huntington disease in an animal model (Harper et al., 2005). This work, together with a previous published experiment from the same group
COMMENT The possible effect of this study on the use of cholinesterase inhibitors is a complex issue because the widespread use of donepezil and other cholinesterase inhibitors is for established AD, not MCI, and the study doesn't speak to that. I believe us
COMMENT Leon Thal and Ron Petersen presented data at the AAN meeting on 4/13/05 that was published today in the NEJM. It compared the effects of donepezil, vitamin E, and placebo in patients who met clinical criteria for amnestic mild cognitive impairment (MCI).
COMMENT The work by Norman Relkin is an intriguing approach to passive immunotherapy. IVIG has been safely administered to thousands of patients and has a good safety record. It is readily available and FDA-approved for other indications. The study presented is o
COMMENT Dr. Norman Relkin and colleagues presented data at this year’s American Academy of Neurology meeting on the use of intravenous immunoglobulin (IVIG) in patients with Alzheimer disease. IVIG is utilized to treat several neurological disorders that have an
COMMENT Prana's decision to cancel the phase II/III "PLACQUE" clinical trial of PBT1 is, of course, disappointing. PBT1 (clioquinol or "CQ") is an old drug that required redevelopment of its synthetic route to meet today's GMP standa
COMMENT I think that the general approach is a real tour de force, and could usher in a potential wave of corrective gene therapy, particularly for developmental disorders that can be identified in utero, or for disorders that affect the immune system, where immu
COMMENT Multiple system atrophy (MSA) is a devastating neurodegenerative disorder that presents with a variety of symptoms that can be categorized broadly into two phenotypic groups, either parkinsonism or cerebellar ataxia. These phenotypes reflect the predomina
COMMENT Why are prion proteins able to propagate in one species and not another? What happens during the rare events when strains of prion proteins are able to breach the species barrier? These critical questions, elegantly addressed by the recent papers from Sur
COMMENT Having read this paper, Larry Goldstein's paper, his group's reply, and comments
